General Pharmacology — MCQs

General Pharmacology Indian Medical PG Practice Questions and MCQs

Question 311: The apparent volume of distribution (Vd) of a drug exceeds the total body fluid volume if the drug is:

A. Sequestrated in body tissues (Correct Answer)
B. Slowly eliminated from the body
C. Poorly soluble in plasma
D. Highly bound to plasma proteins

Explanation: **Explanation:** The **Apparent Volume of Distribution (Vd)** is a theoretical volume that relates the total amount of drug in the body to its concentration in the plasma ($Vd = \text{Amount of drug} / \text{Plasma concentration}$). **Why Option A is correct:** If a drug is highly lipid-soluble or has a high affinity for specific tissues (e.g., adipose tissue, muscle, or bone), it leaves the vascular compartment and becomes **sequestrated in body tissues**. This results in a very low plasma concentration. Since $Vd$ is inversely proportional to plasma concentration, a low denominator leads to a $Vd$ that can far exceed the total body water (~42L). For example, Digoxin has a $Vd$ of ~500L because it binds extensively to cardiac and skeletal muscle. **Why the other options are incorrect:** * **Option B:** Elimination rate (half-life) affects how long a drug stays in the body, but it does not determine the initial distribution pattern between plasma and tissues. * **Option C:** Poor plasma solubility usually implies high lipid solubility, but the $Vd$ only increases if the drug actually binds to or dissolves in extravascular tissues. * **Option D:** Drugs **highly bound to plasma proteins** (e.g., Warfarin) are "trapped" in the vascular compartment. This maintains a high plasma concentration, resulting in a **low Vd**. **High-Yield NEET-PG Pearls:** * **Low Vd (<7L):** Drugs confined to vascular space (e.g., Heparin, Warfarin). * **Medium Vd (15-40L):** Drugs distributed in extracellular fluid (e.g., Gentamicin). * **High Vd (>42L):** Drugs sequestered in tissues (e.g., Chloroquine, Digoxin, Morphine). * **Clinical Significance:** Drugs with a high Vd are **not** easily removed by hemodialysis because most of the drug is outside the blood.

Question 312: Rate of absorption of an intramuscular injection is determined by which of the following factors?

A. Vascularity (Correct Answer)
B. Molecular weight of the drug
C. Volume of the drug
D. Bore of the needle

Explanation: **Explanation:** The rate of absorption of a drug from an intramuscular (IM) site is primarily determined by the **vascularity** (blood flow) of the muscle. 1. **Why Vascularity is Correct:** Absorption from an IM site occurs via simple diffusion from the muscle interstitial fluid into the capillaries. The rate-limiting step for small, water-soluble molecules is the **blood flow** to the area. Muscles with higher vascularity (e.g., Deltoid) exhibit faster absorption rates compared to those with lower vascularity (e.g., Gluteus maximus). This is also why exercise, which increases regional blood flow, accelerates IM drug absorption. 2. **Why Other Options are Incorrect:** * **Molecular Weight:** While it affects the *mechanism* of absorption (large molecules enter via lymphatics), the primary determinant of the *rate* in clinical IM administration is perfusion, not the size of the molecule. * **Volume of the Drug:** Volume primarily affects the pressure at the injection site and potential tissue damage/pain, but it does not dictate the physiological rate of systemic uptake. * **Bore of the Needle:** This determines the ease of administration (viscosity management) and patient discomfort, but has no physiological impact on how the drug crosses the capillary membrane once deposited. **High-Yield Clinical Pearls for NEET-PG:** * **Order of Absorption Rate:** Deltoid > Vastus lateralis > Gluteus maximus (due to decreasing vascularity). * **Depot Preparations:** Drugs like Penicillin G Benzathine or Haloperidol Decanoate are designed as insoluble salts in oil to *intentionally* slow down absorption despite high vascularity. * **Shock/Hypotension:** In patients with circulatory collapse, IM absorption is significantly impaired due to peripheral vasoconstriction; hence, the **Intravenous (IV)** route is preferred in emergencies.

Question 313: Which of the following is an immunostimulant agent?

A. Pirenzepine
B. Levamisole (Correct Answer)
C. Albendazole
D. Methotrexate

Explanation: **Explanation:** **Levamisole** is the correct answer. Originally developed as an anthelmintic, it is a potent **immunomodulator** that acts as an **immunostimulant**. It works by restoring depressed T-cell and macrophage functions, enhancing phagocytosis, and stimulating chemotaxis. While its use has largely been superseded by newer agents, it was historically used in conditions like colon cancer (as an adjuvant with 5-Fluorouracil) [1] and certain autoimmune disorders. **Analysis of Incorrect Options:** * **Pirenzepine (A):** This is a selective **M1 muscarinic receptor antagonist**. It was traditionally used to reduce gastric acid secretion in peptic ulcer disease but is rarely used now due to the advent of PPIs. * **Albendazole (C):** A broad-spectrum **anthelmintic** agent. It works by inhibiting microtubule synthesis (binding to β-tubulin) in parasites. Unlike levamisole, it does not possess significant immunostimulant properties. * **Methotrexate (D):** A folate antimetabolite that acts as an **immunosuppressant** and cytotoxic agent [2]. It inhibits dihydrofolate reductase (DHFR) and is used in cancer chemotherapy and autoimmune diseases like Rheumatoid Arthritis [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Levamisole in Pediatrics:** It is still frequently used in the management of **Steroid-Dependent Nephrotic Syndrome (SDNS)** to maintain remission. * **Side Effects:** A classic side effect of levamisole is **agranulocytosis** [1]; it has also been associated with multifocal leukoencephalopathy. * **Other Immunostimulants:** Remember **Thalidomide** (in Erythema Nodosum Leprosum) [1], **Isoprinosine**, and **Cytokines** (Interferons, IL-2) as other important agents in this category.

Question 314: A drug that binds to a receptor at a site distinct from the active site and alters the affinity of the receptor for the endogenous ligand is a:

A. Competitive antagonist
B. Inverse agonist
C. Partial agonist
D. Allosteric modulator (Correct Answer)

Explanation: ### Explanation **1. Why the Correct Answer is Right (Allosteric Modulator)** In pharmacology, receptors have two primary binding regions: the **orthosteric site** (active site) where the endogenous ligand binds, and **allosteric sites** (distinct, physically separate sites). An **Allosteric Modulator** binds to these distant sites and induces a conformational change in the receptor. This change can either increase (**Positive Allosteric Modulator/PAM**) or decrease (**Negative Allosteric Modulator/NAM**) the affinity or efficacy of the endogenous ligand for its active site. Because it does not compete for the same spot, it is a non-competitive mechanism. **2. Why the Other Options are Incorrect** * **A. Competitive Antagonist:** These drugs bind to the **same active site** as the endogenous ligand. They "compete" for the spot, and their effect can be overcome by increasing the concentration of the agonist (surmountable antagonism). * **B. Inverse Agonist:** These drugs bind to the same receptor as an agonist but produce a pharmacological effect **opposite** to that of the agonist. They require the receptor to have "constitutive activity" (baseline activity in the absence of a ligand). * **C. Partial Agonist:** These bind to the active site but have **low intrinsic activity**. Even at 100% receptor occupancy, they cannot produce a maximal response ($E_{max}$) and can act as antagonists in the presence of a full agonist. **3. NEET-PG High-Yield Pearls** * **Classic Example:** **Benzodiazepines** are PAMs of the $GABA_A$ receptor. They don't open the channel themselves but increase the frequency of channel opening when GABA is present. * **Key Distinction:** Unlike competitive antagonists, allosteric modulators do not shift the dose-response curve in a simple parallel fashion; they typically alter the **slope or the maximum height ($E_{max}$)** of the curve. * **Cinacalcet** is a clinically relevant PAM used in hyperparathyroidism; it increases the sensitivity of calcium-sensing receptors.

Question 315: Pharmacodynamics includes:

A. Drug elimination
B. Drug excretion
C. Drug absorption
D. Mechanism of action (Correct Answer)

Explanation: **Explanation:**Pharmacology is broadly divided into two main branches: **Pharmacokinetics** and **Pharmacodynamics**.**1. Why the Correct Answer is Right:** **Pharmacodynamics** is defined as "what the drug does to the body." [3] It focuses on the biochemical and physiological effects of drugs and their **mechanisms of action** [1]. This includes drug-receptor interactions, signal transduction pathways (like G-protein coupled receptors), and the relationship between drug concentration and effect (dose-response curves) [2].**2. Why the Incorrect Options are Wrong:** Options A, B, and C all fall under the umbrella of **Pharmacokinetics**, which is "what the body does to the drug."* **Drug Absorption (C):** The movement of a drug from its site of administration into the bloodstream.* **Drug Elimination (A) & Excretion (B):** Elimination is the irreversible removal of a drug from the body, which occurs via **Metabolism** (biotransformation, primarily in the liver) and **Excretion** (primarily via the kidneys).**High-Yield NEET-PG Pearls:** * **Mnemonic:** Remember **ADME** for Pharmacokinetics (**A**bsorption, **D**istribution, **M**etabolism, **E**xcretion).* **Receptor Regulation:** A key pharmacodynamic concept is *Down-regulation* (prolonged agonist use leads to decreased receptor number/sensitivity) and *Up-regulation* (prolonged antagonist use leads to increased receptor sensitivity).* **Therapeutic Index (TI):** A pharmacodynamic parameter calculated as $TD_{50} / ED_{50}$. A narrow TI (e.g., Lithium, Digoxin, Warfarin) requires Therapeutic Drug Monitoring (TDM).* **Potency vs. Efficacy:** Efficacy (the maximum response a drug can produce) is clinically more important than potency (the amount of drug needed to produce an effect).

Question 316: All of the following are Phase II reactions except?

A. Acetylation
B. Methylation
C. Cyclization (Correct Answer)
D. Glycine conjugation

Explanation: **Explanation:** Drug metabolism (biotransformation) typically occurs in two phases. **Phase I (Nonsynthetic) reactions** involve the introduction or unmasking of a functional group (–OH, –NH2, –SH), while **Phase II (Synthetic) reactions** involve the attachment of an endogenous moiety to the drug to make it more water-soluble for excretion. **Why Cyclization is the correct answer:** Cyclization is a **Phase I reaction**. It involves the formation of a ring structure from an open-chain compound (e.g., proguanil to cycloguanil). Other Phase I reactions include Oxidation (most common), Reduction, Hydrolysis, and Decarboxylation. **Analysis of Incorrect Options (Phase II Reactions):** Phase II reactions involve **conjugation**. * **A. Acetylation:** A Phase II reaction mediated by N-acetyltransferase (e.g., Isoniazid, Hydralazine). * **B. Methylation:** A Phase II reaction (e.g., Adrenaline to Metanephrine). * **C. Glycine conjugation:** A Phase II reaction (e.g., Salicylates conjugated with glycine to form hippuric acid). * *Other Phase II reactions include Glucuronidation (most common), Sulfation, and Glutathione conjugation.* **High-Yield NEET-PG Pearls:** 1. **Glucuronidation** is the most common Phase II reaction and the only one that occurs in the microsomal fraction (smooth ER); others are non-microsomal. 2. **Oxidation** is the most common Phase I reaction, primarily mediated by **Cytochrome P450** enzymes. 3. **Phase II before Phase I:** While the sequence is usually I then II, some drugs like **Isoniazid** undergo Phase II (Acetylation) followed by Phase I (Hydrolysis). 4. **Slow Acetylators:** Genetic polymorphism in acetylation (NAT2 enzyme) can lead to toxicity with drugs like Isoniazid (peripheral neuropathy) and Hydralazine (Lupus-like syndrome).

Question 317: Which of the following best describes chrono-pharmacology?

A. The study of time-dependent effects of drugs on the body's rhythms. (Correct Answer)
B. The study of the relationship between drug dosage and its effects.
C. The study of unintended or harmful effects of drugs.
D. The study of drugs derived from natural sources.

Explanation: **Explanation:** **Chrono-pharmacology** is the branch of pharmacology that studies how the effects of drugs vary according to biological timing and endogenous periodicities (circadian rhythms). The core principle is that because our physiological functions (like gastric acid secretion, blood pressure, and enzyme activity) fluctuate over a 24-hour cycle, the **pharmacokinetics** (absorption, distribution, metabolism, excretion) and **pharmacodynamics** of a drug also change depending on the time of administration. **Analysis of Options:** * **Option A (Correct):** Accurately defines the study of drug effects in relation to biological rhythms. * **Option B (Incorrect):** This describes **Pharmacodynamics** (specifically the dose-response relationship). * **Option C (Incorrect):** This refers to **Pharmacovigilance** or **Toxicology**, focusing on adverse drug reactions (ADRs). * **Option D (Incorrect):** This defines **Pharmacognosy**, the study of medicines derived from plants or other natural sources. **High-Yield Clinical Pearls for NEET-PG:** 1. **Chrono-therapeutics:** Applying chrono-pharmacology to clinical practice. * **Statins:** Best given at **bedtime** because cholesterol synthesis by HMG-CoA reductase peaks at night. * **Antacids/H2 Blockers:** Most effective at **night** as gastric acid secretion is maximal during late evening. * **Corticosteroids:** Usually given in the **morning** to mimic the natural peak of endogenous cortisol and minimize adrenal suppression. * **NSAIDs for Rheumatoid Arthritis:** Often given at night to combat peak stiffness and pain experienced in the early morning.

Question 318: An antagonist that generates an action opposite to a substance by binding to different receptors is known as:

A. Physical antagonist
B. Chemical antagonist
C. Physiological antagonist (Correct Answer)
D. Pharmacologic antagonist

Explanation: ### Explanation **1. Why Physiological Antagonist is Correct:** A **physiological (or functional) antagonist** occurs when two drugs act on **different receptors** and produce **oppositely directed** physiological effects on the same system. Unlike pharmacological antagonism, there is no competition for the same receptor site. Instead, the drugs activate independent pathways that cancel each other out functionally. * *Classic Example:* **Histamine** (acts on H1 receptors to cause bronchoconstriction) vs. **Adrenaline** (acts on β2 receptors to cause bronchodilation). **2. Why Other Options are Incorrect:** * **Physical Antagonist (A):** Based on the physical property of the drug. For example, **Charcoal** adsorbs alkaloids, preventing their absorption. * **Chemical Antagonist (B):** Two substances react chemically to form an inactive product. No receptors are involved. For example, **Chelating agents** (EDTA) binding to heavy metals or **Antacids** neutralizing gastric acid. * **Pharmacologic Antagonist (D):** The antagonist binds to the **same receptor** as the agonist, preventing the agonist from binding. This can be competitive (reversible) or non-competitive (irreversible). **3. NEET-PG Clinical Pearls & High-Yield Facts:** * **Adrenaline in Anaphylaxis:** Adrenaline is the "physiological antagonist" of histamine and is the drug of choice for anaphylactic shock because it rapidly reverses life-threatening airway obstruction and hypotension via different receptors. * **Glucagon and Insulin:** These are physiological antagonists regarding blood glucose levels (Glucagon increases glucose via glucagon receptors; Insulin decreases it via insulin receptors). * **Key Distinction:** If the question mentions "same receptor," think **Pharmacologic**; if it mentions "different receptor/same system," think **Physiological**.

Question 319: The skeletal muscle relaxant, vecuronium, acts at cholinergic receptors where it exhibits:

A. Affinity but no efficacy (Correct Answer)
B. Efficacy but no affinity
C. Receptor upregulation
D. Affinity and efficacy

Explanation: ### Explanation **1. Why Option A is Correct:** Vecuronium is a **competitive (non-depolarizing) neuromuscular blocker**. In pharmacology, an **antagonist** is defined as a drug that has **affinity** (the ability to bind to a receptor) but lacks **intrinsic activity/efficacy** (the ability to activate the receptor and produce a biological response). Vecuronium competes with acetylcholine (ACh) for the nicotinic receptors ($N_m$) at the neuromuscular junction. By binding to the receptor without activating it, it prevents ACh from binding, thereby inhibiting muscle contraction and causing paralysis. **2. Why Other Options are Incorrect:** * **Option B (Efficacy but no affinity):** This is pharmacologically impossible. A drug must first have affinity (bind) to a receptor before it can exert any efficacy. * **Option C (Receptor upregulation):** While chronic blockade of receptors can lead to upregulation (an increase in receptor number), this is a long-term compensatory mechanism and not the primary mechanism of action of vecuronium. * **Option D (Affinity and efficacy):** This describes an **agonist**. Succinylcholine (a depolarizing blocker) initially shows affinity and efficacy (causing fasciculations) before causing a block. Vecuronium, being non-depolarizing, has no efficacy. **3. NEET-PG Clinical Pearls:** * **Reversibility:** The action of vecuronium can be reversed by Acetylcholinesterase inhibitors like **Neostigmine**, which increase ACh levels to outcompete the blocker. * **Sugammadex:** A specific reversal agent that encapsulates vecuronium molecules, rendering them inactive. * **Metabolism:** Vecuronium is primarily excreted via **bile** (partially metabolized by the liver), making it safer than pancuronium in patients with renal failure. * **Cardiovascular Stability:** Unlike d-tubocurarine, vecuronium does not cause significant histamine release or ganglion blockade, ensuring hemodynamic stability.

Question 320: Succinylcholine is contraindicated in all the following conditions except:

A. Burns
B. Muscular dystrophy
C. Rapid sequence intubation (Correct Answer)
D. Neuromuscular disease

Explanation: **Explanation:** Succinylcholine is a **depolarizing neuromuscular blocker** that acts as an agonist at the nicotinic acetylcholine receptors (nAChR). Its primary clinical utility is in **Rapid Sequence Intubation (RSI)** because of its rapid onset (30–60 seconds) and short duration of action (5–10 minutes), allowing for quick airway control. **Why Option C is Correct:** Rapid sequence intubation is the **primary indication** for Succinylcholine, not a contraindication. It is preferred in emergency settings where the patient has a "full stomach" to prevent aspiration. **Why Other Options are Contraindicated:** The common mechanism for contraindication in options A, B, and D is the risk of **life-threatening hyperkalemia**. * **Burns (Option A):** After 24–48 hours of a major burn, there is an "upregulation" of extrajunctional acetylcholine receptors. Succinylcholine causes prolonged depolarization of these receptors, leading to a massive efflux of potassium. * **Muscular Dystrophy (Option B):** In conditions like Duchenne muscular dystrophy, Succinylcholine can cause rhabdomyolysis, hyperkalemia, and cardiac arrest. * **Neuromuscular Disease (Option D):** Conditions like stroke, spinal cord injury, or prolonged immobilization also lead to receptor upregulation, making the patient highly susceptible to hyperkalemic cardiac arrest. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Agonist at nAChR causing persistent depolarization (Phase I block). * **Metabolism:** Rapidly hydrolyzed by **Pseudocholinesterase** (Butyrylcholinesterase). * **Side Effects:** Muscle fasciculations (can be prevented by a small dose of non-depolarizing blocker), malignant hyperthermia (treated with **Dantrolene**), and increased intraocular/intragastric pressure. * **Genetic Variation:** Patients with atypical pseudocholinesterase experience prolonged apnea after Succinylcholine administration.

Practice by Chapter

Pharmacokinetics: Absorption and Distribution

Practice Questions

Pharmacokinetics: Metabolism and Excretion

Practice Questions

Pharmacodynamics and Receptor Theory

Practice Questions

Drug-Receptor Interactions and Dose-Response

Practice Questions

Pharmacogenetics and Personalized Medicine

Practice Questions

Adverse Drug Reactions and Toxicity

Practice Questions

Drug Interactions

Practice Questions

Drug Development and Regulation

Practice Questions

Pediatric and Geriatric Pharmacology

Practice Questions

Placental Transfer and Lactation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free